HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Picibanil

A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.
Also Known As:
NSC-B116209; OK-432; Picibanyl; Streptococcal OK-432; Streptococcal Preparation OK-432; NSC B116209; NSCB116209; OK 432; OK432; Streptococcal OK 432; Streptococcal OK432; Streptococcal Preparation OK 432; Streptococcal Preparation OK432
Networked: 1131 relevant articles (198 outcomes, 160 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Okamoto, Masato: 21 articles (01/2018 - 11/2002)
2. Sato, Mitsunobu: 13 articles (07/2013 - 11/2002)
3. Ohta, Nobuo: 11 articles (03/2022 - 03/2003)
4. Tano, Tomoyuki: 11 articles (07/2013 - 11/2002)
5. Oshikawa, Tetsuya: 11 articles (09/2006 - 11/2002)
6. Fukase, Shigeru: 10 articles (03/2022 - 03/2003)
7. Ryoma, Yoshiki: 10 articles (08/2007 - 09/2002)
8. Moriya, Yoichiro: 8 articles (01/2008 - 11/2002)
9. Aoyagi, Masaru: 7 articles (02/2014 - 03/2003)
10. Kan, Shin: 7 articles (07/2013 - 11/2004)

Related Diseases

1. Neoplasms (Cancer)
11/01/1987 - "However, it was also observed that most of the R1-3B3- cells that killed MADB106 tumor cells were: 1) phenotypically or functionally different from either cytotoxic T-cells or typical NK cells; 2) observed only in MADB106 tumor-bearing rats challenged with OK-432; 3) not present on day 1-2 following OK-432 injection, the time when YAC-1 killing was maximally augmented; and 4) present in high numbers in a secondary response following reinoculation of the MADB106 tumor cells into cured rats. "
11/01/1992 - "The present study was designed to determine the optimal therapeutic protocol for OK-432, a streptococcal preparation, and to clarify the kinetics of various immunological parameters following intracutaneous administration of OK-432 in 39 disease-free postoperative patients with early cancer. "
09/01/1991 - "A randomized prospective study of 1011 gastrectomized cancer patients treated with oral OK432 showed significantly good results, especially in n(+) cases with curative resection. "
10/01/2005 - "Anti-tumor effect of OK-432 in TLR9-deficient mice was significantly but partially reduced as compared with that in wild-type mice, while the effect of OK-432 was almost completely eliminated in TLR4-deficient mice. "
12/15/1994 - "However, analysis based on stage showed that a preoperative intratumoral injection of OK-432 significantly improved the 5-year survival rate of patients with Stage III cancer (P = 0.0229), at 47.7% for the OK-432 group and 27.5% for the control group. "
2. Lymphangioma (Cavernous Lymphangioma)
3. Stomach Neoplasms (Stomach Cancer)
4. Neoplasm Metastasis (Metastasis)
5. Ranula

Related Drugs and Biologics

1. Picibanil
2. Interleukin-2 (IL2)
3. Tegafur
4. Fluorouracil (Carac)
5. Sclerosing Solutions (Sclerosing Agents)
6. Immunologic Factors (Immunomodulators)
7. Fibrinogen (Factor I)
8. Mitomycin (Mitomycin-C)
9. Cisplatin (Platino)
10. Cytokines

Related Therapies and Procedures

1. Therapeutics
2. Sclerotherapy
3. Immunotherapy
4. Intralesional Injections
5. Pleurodesis